PMC:4159494 / 21622-22552 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/4159494","sourcedb":"PMC","sourceid":"4159494","source_url":"https://www.ncbi.nlm.nih.gov/pmc/4159494","text":"Sarcopenia has its own assortment of detrimental clinical outcomes. Disability assessed by questions concerning activities of daily living can aggravate the development of sarcopenia, especially in those with severe sarcopenia (defined as a ASM index  \u003c 8.50 kg/m2 in men and \u003c5.75 kg/m2 in women); due to its bidirectional nature, sarcopenia may lead to disability, and disability may further initiate sarcopenia [18, 62], thus creating an infinite cycle. Elderly individuals who lose fat-free mass (FFM) are over two times more likely to report disability compared to those who do not lose FFM [63]. Additionally, sarcopenia is also associated with increased mortality in the oldest (80+ years of age) frail elderly [64]. Smaller muscle mass and greater fat infiltration in muscle has been shown to have a negative relationship to lower extremity performance repeatedly measured by walking and standing/sitting assessments [65].","tracks":[]}